2 results
Approved WMOWill not start
In patients who are aged 18 years and older with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC)and positive programmed cell death ligand1 (PD-L1)expression (defined by combined positive score [CPS]*1) who have not received…
Approved WMORecruiting
This entry-into-human (EIH) Phase Ia/Ib study aims to establish the safety,pharmacokinetics, immunogenicity, and pharmacodynamics of RO7284755 (alone or incombination with atezolizumab) and to evaluate its anti-tumor activity.